Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010 Sep 30, 2010 Jun 30, 2010 Mar 31, 2010
Notes payable 72,100 55,800 60,900 61,100 55,600 37,200 51,600 57,200 48,800 40,700 42,400 87,700 83,900 78,800 76,100 36,300 28,100 18,500 13,100 17,900
Convertible notes — — — — — — — — — — — — — — — 648,900 642,500 636,000 629,700 —
Accounts payable 287,400 283,200 300,000 316,500 283,200 267,800 237,000 218,500 233,100 210,600 200,600 203,000 200,400 190,100 200,300 200,500 222,500 206,300 198,900 257,900
Accrued compensation 292,800 267,900 211,600 168,100 269,100 241,900 195,400 156,500 223,700 204,900 162,000 129,500 200,600 186,900 170,900 118,800 182,400 169,100 148,200 98,400
Accrued legal settlement expenses — — — — — — — — — — — — — — — — — 609,900 — —
Other accrued expenses 905,000 960,100 833,900 702,400 597,500 632,600 610,300 624,600 589,600 596,200 558,800 548,600 470,100 467,900 474,200 471,100 436,800 432,200 386,900 388,400
Income taxes — — — — 38,900 16,900 — — — 2,500 — — — — — — 16,100 21,000 43,200 20,700
Liabilities of discontinued operations — — — — — 3,300 3,600 4,700 — — — — — — — — — — — —
Current liabilities 1,557,300 1,567,000 1,406,400 1,248,100 1,244,300 1,199,700 1,097,900 1,061,500 1,095,200 1,054,900 963,800 968,800 955,000 923,700 921,500 1,475,600 1,528,400 2,093,000 1,420,000 783,300
Long-term debt, excluding current maturities 2,085,300 2,088,600 2,091,800 2,095,100 2,098,300 2,101,500 2,104,600 2,107,700 1,512,400 1,515,500 1,514,900 1,514,700 1,515,400 1,516,200 1,510,300 1,529,500 1,534,200 1,546,000 888,700 877,800
Long-term convertible notes — — — — — — — — — — — — — — — — — — — 623,500
Other liabilities 1,010,100 871,200 698,300 752,000 762,200 730,300 725,200 718,900 709,100 746,200 733,300 719,800 705,800 615,600 459,100 477,500 464,400 416,700 369,200 377,100
Non-current liabilities 3,095,400 2,959,800 2,790,100 2,847,100 2,860,500 2,831,800 2,829,800 2,826,600 2,221,500 2,261,700 2,248,200 2,234,500 2,221,200 2,131,800 1,969,400 2,007,000 1,998,600 1,962,700 1,257,900 1,878,400
Total liabilities 4,652,700 4,526,800 4,196,500 4,095,200 4,104,800 4,031,500 3,927,700 3,888,100 3,316,700 3,316,600 3,212,000 3,203,300 3,176,200 3,055,500 2,890,900 3,482,600 3,527,000 4,055,700 2,677,900 2,661,700
Preferred stock, $.01 par value; none issued — — — — — — — — — — — — — — — — — — — —
Common stock, $.01 par value 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100 3,100
Additional paid-in capital 3,353,700 3,249,700 3,193,400 3,124,700 3,032,800 3,005,200 2,975,600 2,951,200 2,900,600 2,854,100 2,824,200 2,794,100 2,761,800 2,725,500 2,702,400 2,828,800 2,815,500 2,774,800 2,751,700 2,736,200
Accumulated other comprehensive loss (408,600) (293,400) (216,100) (224,000) (226,600) (252,100) (282,100) (265,900) (244,600) (244,800) (258,600) (218,500) (241,400) (179,000) (100,300) (131,600) (152,900) (105,400) (166,300) (122,800)
Retained earnings 5,894,800 5,411,900 5,138,800 4,790,500 4,646,700 4,363,600 4,089,400 3,761,900 3,832,100 3,602,900 3,387,600 3,134,900 2,969,300 2,752,200 2,530,300 2,342,300 2,225,900 2,030,200 2,723,000 2,498,700
Treasury stock, at cost (1,090,000) (1,260,600) (1,333,200) (1,076,400) (992,800) (1,033,900) (1,064,100) (1,113,200) (654,100) (645,700) (517,500) (255,000) (183,200) (196,100) (171,600) (176,900) (133,900) (243,200) (223,500) (170,400)
Total Allergan, Inc. stockholders’ equity 7,753,000 7,110,700 6,786,000 6,617,900 6,463,200 6,085,900 5,721,900 5,337,100 5,837,100 5,569,600 5,438,800 5,458,600 5,309,600 5,105,700 4,963,900 4,865,700 4,757,700 4,459,500 5,088,000 4,944,800
Noncontrolling interest 10,000 8,300 8,300 7,100 6,300 27,200 25,400 25,300 25,500 24,700 22,600 22,300 22,800 22,800 24,800 22,400 23,400 24,900 21,700 21,900
Total equity 7,763,000 7,119,000 6,794,300 6,625,000 6,469,500 6,113,100 5,747,300 5,362,400 5,862,600 5,594,300 5,461,400 5,480,900 5,332,400 5,128,500 4,988,700 4,888,100 4,781,100 4,484,400 5,109,700 4,966,700
Total liabilities and equity 12,415,700 11,645,800 10,990,800 10,720,200 10,574,300 10,144,600 9,675,000 9,250,500 9,179,300 8,910,900 8,673,400 8,684,200 8,508,600 8,184,000 7,879,600 8,370,700 8,308,100 8,540,100 7,787,600 7,628,400

Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan Inc. current liabilities increased from Q2 2014 to Q3 2014 but then slightly decreased from Q3 2014 to Q4 2014.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan Inc. non-current liabilities increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan Inc. total liabilities increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.
Total Allergan, Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan Inc. total Allergan, Inc. stockholders’ equity increased from Q2 2014 to Q3 2014 and from Q3 2014 to Q4 2014.